Project

Thérapeutic innovations :

DIVE: Parkinson's disease is characterized by a cerebral depletion of dopamine that cannot be administered orally. We restore the circadian dopamine cycle by administering dopamine intracerebroventricularly using an intra-abdominal pump. Anaerobic dopamine has demonstrated efficacy and safety in 3 in vivo models and transferred to the start-up InBrain Pharma allowing the phase I-II clinical trial showing safety and efficacy in a first of 20 patients.

GIFT: A neuroprotective and neurorestored biotherapy based on the use of the powerful physiological repair system contained in platelets, modified to be compatible with the central nervous system. After preclinical validation, the preparation of the clinical trial for amyotrophic lateral sclerosis is underway via transfer to the InVenis Biotherapies startup. An intranasal nanoparticle solution is being developed for less severe diseases. 

Team:

UMRS 1172: David Devos, Caroline Moreau, Jean Christophe Devedjian, Anne Sophie Rolland, Pauline Guyon, Charlotte Laloux, Flore Gouel, Kelly Timmerman, Cédrick Lachaud, Aurélie Jonneaux, Maud Petrault, Laura Mahoney-Sanchez, Hind Bouchaoui, Karim Belarbi, Marie Amandine Bonte, Emma Theerens, Florent Auger, Clemence Leboullenger, Renaud Lopes, Nacim Betrouni, Jean Pierre Pruvo, Gregory Kuchcinski, Romain Viard, Luc Defebvre, Véronique Danel, Dominique Deplanque, Régis Bordet

International laboratories: NeuroTMULille International Laboratory, Univ. Lille & Taipei Medical University, Lille (France) & Taipei (Taiwan) : Thierry Burnouf, Liling Delila, Ouada Nebie, Chou MingLi

Local collaborations:

Pharm Inject, ULR 7375 GRITA : Pascal Odou, Natacha Carta, Christine Barthelemy
Central Pharmacy Lille University Hospital : Pascal Odou, Damien Lannoy
Institute of Electronics, Microelectronics and Nanotechnology (IEMN), UMR CNRS8520 : Sabine Szunerits, Rabah Boukherroub, Alexandre Barras, Quentin Pagneux
UMRS1172: David Blum (équipe A&T)
ULR4483 - IMPact of the Chemical Environment on Health (IMPECS) : Guillaume Garçon
GIMAP EA3064 & French Blood Establishment Auvergne-Rhône-Alpes : Fabrice COGNASSE 

Startup (spin off of the research team ):

InBrain Pharma https://www.inbrainpharma.com/ Matthieu Fisichella, Alexandre Demailly, Marine Rebier, Caroline Moreau, David Devos
InVenis Biotherapies (in creation) : Matthieu Fisichella, Alexandre Demailly, Marine Rebier, Caroline Moreau, David Devos, Thierry Burnouf

Industrial collaborations

Flowonix, Tricumed, et Renishaw

Labels / Funding

Satt-Nord, Cabri, Crédit Agricole Foundation, University Foundation , I-Site

Highlights

The IntraVentricular Dopamine (DIVE) project to treat severe fluctuations in Parkinson's disease led to an academic patent transferred to the InBrain Pharma Startup, Spin off of our research unit (co-financed by Finovam and. NFA) which, has won 4 awards (Eurasanté, Fondation de l'Université de Lille, ILAB Prize, DeepTech Prize) and is already in clinical phase 1 and 2b with a first improved Parkinson's patient without any safety problems! (Illustration 1)

The biotherapy project using modified platelet lysates (GIFT) has won the I-SITE-ULNE and Crédit Agricole Foundation awards for Prematurity, has led to 3 academic patents transferred the InVenis Biotherapy Startup (co-financed by Finovam and NFA), Spin off from our research unit, which will launch the phase 1 and 2b therapeutic trial in amyotrophic lateral sclerosis. (Illustration 2)

Two new academic projects in the preclinical phase are pursuing the development of this new therapeutic concept, including ACTIVE based on the DIVE model with the recent obtaining of regional funding (Stimulus) and Nano-GIFT, which is developing a nanoparticle-based formulation for intranasal administration for less severe diseases of the central nervous system. (Illustration 3)

Publications

Seven Solutions for Neuroprotection in Parkinson's Disease.Devos D, Hirsch E, Wyse R. Mov Disord. 2020 Nov 13.

Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease. Moreau C, Rolland AS, Pioli E, Li Q, Odou P, Barthelemy C, Lannoy D, Demailly A, Carta N, Deramecourt V, Auger F, Kuchcinski G, Laloux C, Defebvre L, Bordet R, Duce J, Devedjian JC, Bezard E, Fisichella M, Devos D. Neurobiol Dis. 2020;139:104846.

The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. Gouel F, Do Van B, Chou ML, Jonneaux A, Moreau C, Bordet R, Burnouf T, Devedjian JC, Devos D. J Tissue Eng Regen Med. 2017;11:3236-3240.